-
Samsung expects 780% quarterly operating profit jump on AI boom
-
As species decline, green turtles offer glimmer of hope
-
Guardians survive with 9-3 win over White Sox
-
Brothers Scott and Beauden Barrett named to start for All Blacks
-
Saudi Arabia says 3 dead at airports after Houthis claim attacks
-
EU trade chief seeks to dial down China tensions
-
Stocks slide as oil sees volatile trading day over Iran war fears
-
'Never again Bolsonaro': thousands march ahead of Brazil election runoff
-
Microsoft pushes AI vision with new, expensive Surface laptop
-
After botched execution, US woman was nearly taken off life support before revival
-
Five children among 28 killed in Russian strikes on Ukraine
-
Searing AIDS drama 'Elsinore' opens London film festival
-
Odell Beckham Jr signs with Minnesota Vikings
-
Evicted pensioner who sparked Spain housing protests dies: tenant union
-
Saudi Arabia says three dead at airports after Houthis claim attacks
-
Golf star Rahm quitting LIV tour over 'unacceptable' terms
-
Trump plans to turn Florida golf course into presidential retreat
-
Thousands march fearing return of a Bolsonaro presidency in Brazil
-
WHO says cannot conduct full risk assessment on Russia plague reports
-
French PM denies police ordered to confront student protesters
-
After botched execution, US woman is awake and shackled to bed
-
Rubio touts US power, calls on Europe to emerge from 'slumber'
-
New Zealand fly-half Mo'unga ruled out of Australia Tests
-
Trump says 'we don't think' Russian plague is bio-weapon
-
Protests in major Turkish city after mayor defects to Erdogan party
-
Five children among 26 killed in Ukraine after Russian strikes
-
Climate change strips island's title of largest penguin colony: study
-
Man City should 'accept' punishment for rule breaches, says Lineker
-
Rubio says West must choose between national power or decline
-
US woman who survived botched execution is awake and speaking
-
Russia's plague scare: What we know
-
From 1800s to modern pharma: a Nobel-winning chemistry quest
-
French luxury giant to fund redevelopment of two Paris streets: city hall
-
Southampton boss Eckert given suspended ban over 'Spygate'
-
Trump wants to turn Florida golf course into presidential retreat
-
Russia warns of 'false' information as second plague case reported
-
Mayor of Turkish opposition stronghold defects to Erdogan party
-
IEA ready to release more oil reserves if necessary
-
Children among heavy casualties in Ukraine after Russian strikes
-
HSBC 'consults' over UK unit job cuts amid AI adoption
-
Court orders German ex-spy chief kept in jail after spying, treason arrest
-
UK court quashes five ex-traders' Libor rate rigging convictions
-
Guinea caps bottled water prices after sachets banned
-
XM Receives “Global Customer Experience Leader Award 2026” at the TrustFinance Performance Awards
-
Spared, married, hanged: the last weeks of Iranian protester Alireza Sepahi
-
Stocks slide as oil climbs on Mideast flareup
-
Nobel physics winner's pride at pioneering AI role
-
Heavy casualties in Ukraine after Russian strikes
-
IMF preparing El Nino assistance, concerned about AI bubble burst: chief to AFP
-
French wine harvest set to hit historic low
Report paves way for EU to renew glyphosate use
The European Food Safety Authority said on Thursday it had not found "any critical areas of concern" preventing the controversial and widely used herbicide glyphosate from being reauthorised for use in the EU.
Environmental groups lashed out at the announcement, saying there was scientific evidence that glyphosate may cause cancer, poison aquatic life and can be fatal to key pollinators like bees.
The European Union agency's long-awaited assessment report noted that there were gaps in the data in some areas, and that it had "identified a high long-term risk to mammals in 12 out of 23 proposed uses of glyphosate".
But the EFSA said that it only considered a concern "critical" when it affected all proposed uses of the substance, which would prevent it from being renewed.
The study, which was submitted to the European Commission and member states, will serve as a basis for the EU's upcoming decision on whether to renew the use of glyphosate in the bloc for another five years.
The current authorisation runs out on December 15.
The full report, which is expected to be released by the end of the month, is based on some 24,000 studies, as well as responses from 90 experts from member states, the EFSA said.
The agency said that because of a lack of data it had not finalised its risk assessment of glyphosate's impact on aquatic plants.
It also did not give advice on the risks of food consumption, "due to incomplete data about the amount of glyphosate residues in rotational crops such as carrots, lettuce and wheat".
- 'Toxic for people and the environment' -
But it added that this was not expected to lead to toxicological safety levels being exceeded, "so no critical concern was identified".
Environmental campaign group Greenpeace reacted with dismay to the news.
"For years the evidence of glyphosate's toxicity for people and the environment has been stacking up but the European Food Safety Authority has once again decided to sweep it under the carpet," said Greenpeace EU pesticides campaigner Eva Corral.
Another campaign group, Corporate Europe Observatory, said the EFSA's advice "is a slap in the face".
"How could EFSA give glyphosate a thumbs-up based on primarily shoddy, corporate-led scientific studies?" the group said.
Glyphosate is the main ingredient in the widely used Roundup weedkiller from US agrochemical firm Monsanto, which was bought by German chemicals giant Bayer in 2018.
Bayer has since faced a wave of lawsuits in the United States over claims that glyphosate causes cancer. The firm denies such claims, but has paid out billions of dollars to settle legal disputes.
The World Health Organization's International Agency for Research on Cancer said in 2015 that glyphosate was "probably carcinogenic".
France's medical research institute INSERM said in 2021 that glyphosate has a "moderate presumed link" with the cancer non-Hodgkin lymphoma.
Despite that, the European Chemicals Agency said last year the available evidence did not justify classifying the substance as a carcinogen.
The EFSA had originally planned to release its study in the second half of 2022, but said it delayed publication due to an "unprecedented" number of comments on the issue.
W.Morales--AT